NASDAQ:SPRO - Nasdaq - US84833T1034 - Common Stock - Currency: USD
2.5
+0.37 (+17.37%)
The current stock price of SPRO is 2.5 USD. In the past month the price increased by 278.79%. In the past year, price increased by 76.06%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.12 | 328.74B | ||
AMGN | AMGEN INC | 13.88 | 154.96B | ||
GILD | GILEAD SCIENCES INC | 14.22 | 136.93B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.52B | ||
REGN | REGENERON PHARMACEUTICALS | 11.06 | 52.94B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.71B | ||
ARGX | ARGENX SE - ADR | 99.7 | 35.00B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.29 | 26.55B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.03B | ||
NTRA | NATERA INC | N/A | 21.54B | ||
BIIB | BIOGEN INC | 8.2 | 19.02B | ||
UTHR | UNITED THERAPEUTICS CORP | 12.72 | 14.38B |
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company is headquartered in Cambridge, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
SPERO THERAPEUTICS INC
675 Massachusetts Ave Ste 14
Cambridge MASSACHUSETTS 02139 US
CEO: Ankit Mahadevia
Employees: 32
Phone: 18572421600
The current stock price of SPRO is 2.5 USD. The price increased by 17.37% in the last trading session.
The exchange symbol of SPERO THERAPEUTICS INC is SPRO and it is listed on the Nasdaq exchange.
SPRO stock is listed on the Nasdaq exchange.
9 analysts have analysed SPRO and the average price target is 5.1 USD. This implies a price increase of 104% is expected in the next year compared to the current price of 2.5. Check the SPERO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SPERO THERAPEUTICS INC (SPRO) has a market capitalization of 139.78M USD. This makes SPRO a Micro Cap stock.
SPERO THERAPEUTICS INC (SPRO) currently has 32 employees.
The Revenue of SPERO THERAPEUTICS INC (SPRO) is expected to decline by -100% in the next year. Check the estimates tab for more information on the SPRO EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SPRO does not pay a dividend.
SPERO THERAPEUTICS INC (SPRO) will report earnings on 2025-08-04, after the market close.
SPERO THERAPEUTICS INC (SPRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.28).
The outstanding short interest for SPERO THERAPEUTICS INC (SPRO) is 1.55% of its float. Check the ownership tab for more information on the SPRO short interest.
ChartMill assigns a technical rating of 8 / 10 to SPRO. When comparing the yearly performance of all stocks, SPRO is one of the better performing stocks in the market, outperforming 98.8% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to SPRO. While SPRO seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months SPRO reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS decreased by -341.51% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -89.77% | ||
ROE | -206.31% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 78% to SPRO. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 0.01% and a revenue growth -100% for SPRO